Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls

Pedersen, Court; Breindahl, Morten; Aggarwal, Naresh; Berglund, Johan; Oroszlán, György; Silfverdal, Sven‐Arne; Szüts, P; O’Mahony, Michael; David, Marie-Pierre; Dobbelaere, Kurt; Dubin, Gary; Descamps, Dominique

doi:10.1016/j.jadohealth.2011.10.009

Cited by 28 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percentage of reported AEs was higher following Twinrix TM than in the group receiving concurrent Vaqta and Recombivax-HB/H-BVaxII [36]. [39,40,52]. However, the incidence of grade 3 pain was slightly higher when Twinrix pediatric TM was co-administered with HPV vaccine than when administered alone [40].…”

Section: Ambirix Tmmentioning

confidence: 87%

“…[39,40,52]. However, the incidence of grade 3 pain was slightly higher when Twinrix pediatric TM was co-administered with HPV vaccine than when administered alone [40]. Both local and general symptoms were more frequently reported after co-administered hepatitis A/B and MMR vaccination (48% and 46%, respectively) compared to co-administered hepatitis A/B and DTPa-IPV/Hib vaccination (18% and 32%, respectively) [52].…”

Section: Ambirix Tmmentioning

confidence: 98%

“…From month 7 to year 10 after the first vaccine dose, all subjects (100%) remained seropositive for anti-HAV antibodies [10,15,[38][39][40][41][42][43][44][45]. After the third dose (month 7), the anti-HAV antibody GMC ranged from 4174 to 9257 mIU/ml.…”

Section: Twinrix Pediatric Tmmentioning

confidence: 99%

“…At month 7, all subjects (100%) were seroprotected for antiHBs antibodies [38][39][40][41][42][43][44]. Follow-up data were available up to 10 years after the primary vaccination; the percentage of seroprotected subjects decreased slightly, but remained above 85% [10,15,43].…”

Section: Twinrix Pediatric Tmmentioning

confidence: 99%

See 3 more Smart Citations

Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review

Bakker¹,

Bunge²,

Marano

et al. 2016

Expert Review of Vaccines

View full text Add to dashboard Cite

Background: Hepatitis A and B are two of the most common vaccine-preventable diseases and vaccination for Hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for those at risk of contracting HAV and/or HBV through their occupation, travel or lifestyle. Objective: To describe the vaccine efficacy, immunogenicity, effectiveness and safety of the combined vaccine against hepatitis A and hepatitis B. Methods: A systematic review of the literature published between 1990 and 2015.Results: Anti-HAV seropositivity rates ranged from 96.2% to 100% and anti-HBs seroprotection rates from 82% to 100%. Antibodies persisted up to 15 years and geometric mean concentration (GMC) remained above the seropositivity cut-off value for both. Anti-HAV and anti-HBs immune responses were lower in less immunocompetent individuals one month after completion of the immunization schedule. The safety profiles of Twinrix TM and monovalent hepatitis A and B vaccines were similar. Conclusion: The vaccine offers satisfactory long-term immunogenicity rates, expected duration of protection and safety profile similar to the monovalent hepatitis A or B vaccines.

show abstract

Section: Ambirix Tmmentioning

confidence: 87%

Section: Ambirix Tmmentioning

confidence: 98%

Section: Twinrix Pediatric Tmmentioning

confidence: 99%

Section: Twinrix Pediatric Tmmentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review

Bakker¹,

Bunge²,

Marano

et al. 2016

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…15 During the following 10 y, other TLR agonists besides BCG were the subject of an intense wave of preclinical investigations. 16 The safety in patients and ability to induce therapeutic effects against a variety of tumors was confirmed for some of these, for example, monophosphoryl lipid A (MPL), 17 imiqimod, 18 and OM-174. 19 Even if the molecular mechanisms of TLR agonist-mediated tumor regression are not well understood, several mechanisms have been characterized.…”

Section: Introductionmentioning

confidence: 98%

TLR4/IFNγ pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer models

et al. 2015

View full text Add to dashboard Cite

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

Arbyn

Simoens

et al. 2018

Cochrane Database of Systematic Reviews

342

241

View full text Add to dashboard Cite

show abstract

Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls

Cited by 28 publications

References 31 publications

Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review

Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review

TLR4/IFNγ pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer models

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

Contact Info

Product

Resources

About